U.S. Markets open in 1 hr 40 mins

Synthetic Biologics, Inc. (SYN)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
1.01+0.05 (+5.21%)
At close: 3:59PM EDT
People also watch
ZIOPIDRAFCSCCRMDSGYP
Full screen
Previous Close0.96
Open1.05
Bid0.85 x 3000
Ask1.08 x 1400
Day's Range0.95 - 1.05
52 Week Range0.41 - 1.90
Volume3,925,508
Avg. Volume1,554,885
Market Cap129.75M
Beta1.63
PE Ratio (TTM)-6.16
EPS (TTM)-0.16
Earnings DateMay 3, 2017 - May 8, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.25
Trade prices are not sourced from all markets
  • Synthetic Biologics (SYN) in Focus: Stock Moves 7.7% Higher
    Zacks2 days ago

    Synthetic Biologics (SYN) in Focus: Stock Moves 7.7% Higher

    Synthetic Biologics (SYN) was a big mover last session, as the company saw its shares rise nearly 8% on Friday amid huge volumes.

  • ACCESSWIRE2 days ago

    Today's Research Reports on Stocks to Watch: Synthetic Biologics and Microbot Medical

    NEW YORK, NY / ACCESSWIRE / September 18, 2017 / Shares of both Synthetic Biologics and Microbot Medical soared this past Friday after the companies had exciting news to share with investors. Synthetic ...

  • Synthetic Biologics Announces Closing of $12 Million Convertible Preferred Stock Financing
    PR Newswire8 days ago

    Synthetic Biologics Announces Closing of $12 Million Convertible Preferred Stock Financing

    ROCKVILLE, Md., Sept. 12, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today the closing of a privately placed stock purchase transaction for the sale of redeemable convertible preferred stock to an affiliate of MSD Partners, L.P. for aggregate gross proceeds of $12 million. Synthetic Biologics intends to use proceeds from the Preferred Stock transaction for general corporate purposes, including the continued advancement of SYN-004 (ribaxamase), the Company's Breakthrough Therapy Designation drug candidate designed to prevent antibiotic-mediated C. difficile infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR) in the gut microbiome.